Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGenprex Inc

Genprex Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.0601 USD -0.08 ( 3.73%)
Last update at 2026-11-05T18:22:00Z
VOLUME
69029
Market Cap
9.86M

Momentum Score

…

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.95
Low
2.25
High
52 Week Price Range
1.04
Low
55.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.14
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-338.74%
Net Debt
-7.83M
ROCE
-194.32%
Diluted EPS TTM
-17.40

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -16.23M -21.11M -30.86M -23.74M -19.60M
Net income -16.23M -21.11M -30.86M -29.46M -19.59M
Selling general administrative 6.09M 10632.03M 13.44M 12.30M 10.97M
Selling and marketing expenses - 10621.40M 13.43M - -
Gross profit - -0.01M -0.02M -23.83M -
Reconciled depreciation 0.00M 0.01M 0.02M 0.03M 0.02M
Ebit - -21.11M -31.08M -23.83M -19.60M
Ebitda -15.49M -21.10M -31.06M -23.81M -19.58M
Depreciation and amortization - 0.01M 0.02M 0.03M 0.02M
Operating income -15.52M -21.17M -31.08M -23.83M -19.60M
Other operating expenses 15.52M 21.17M 31.08M 23.83M 19.60M
Interest expense 0.74M 0.00M - 18.11M 0.01M
Interest income - 0.06M 0.23M 0.09M 0.01M
Net interest income -0.74M 0.06M 0.23M 0.09M 0.01M
Income tax expense - -21367.17M -0.00M 5.72M -0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 15.52M 21.17M 31.06M 23.83M 19.60M
Cost of revenue - 0.01M 0.02M 23.83M -
Total other income expense net -0.71M 0.06M 0.22M 0.09M 0.01M
Net income from continuing ops -16.23M -21.11M -31.45M -23.74M -19.60M
Net income applicable to common shares - - - - -19.60M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 10.16M 4.12M 10.67M 25.09M 42.86M
Intangible assets - - 0.77M 0.70M 0.64M
Other current assets 0.53M 0.48M 0.79M 0.48M 0.51M
Total liab 2.20M 2.50M 3.25M 2.81M 1.59M
Total stockholder equity 7.96M 1.62M 7.42M 22.27M 41.28M
Other current liab 1.43M 1.43M 1.86M 2.37M 0.61M
Common stock 0.00M 0.01M 0.00M 0.05M 0.05M
Capital stock 0.00M 0.01M 0.00M 0.05M 0.05M
Retained earnings -171.03M -154.80M -133.69M -102.83M -78.02M
Other assets - 0.00M 0.00M - 3.03M
Cash 7.83M 1.60M 6.74M 20.95M 38.63M
Total current liabilities 2.17M 2.50M 3.25M 2.81M 1.59M
Net debt -7.83M -1.60M -6.74M -20.95M -38.63M
Other stockholder equity 178.99M 156.41M 141.10M 125.05M 119.25M
Property plant equipment - - - - 0.05M
Total current assets 8.36M 2.08M 7.53M 21.47M 39.14M
Net tangible assets - - - - 40.63M
Short term investments - 1600.06M - - -
Net receivables - - 0.00M 0.03M 0.00M
Accounts payable 0.74M 1.07M 1.40M 0.44M 0.97M
Accumulated other comprehensive income - - 0.00M - -
Non currrent assets other 1.80M 2.05M 2.36M 2.89M 3.03M
Non current assets total 1.80M 2.05M 3.14M 3.61M 3.72M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M 0.08M 0.10M -0.08M
Change to liabilities - - - 0.00M 0.78M
Total cashflows from investing activities - 0.00M -0.07M - -0.08M
Total cash from financing activities 21.54M 12.01M 10.59M 0.01M 25.68M
Change to operating activities - - - 1.77M 0.23M
Net income -16.23M -21.11M -30.86M -23.74M -19.60M
Change in cash 6.23M -5.14M -14.22M -17.67M 11.31M
Begin period cash flow 1.60M 6.74M 20.95M 38.63M 27.32M
End period cash flow 7.83M 1.60M 6.74M 20.95M 38.63M
Total cash from operating activities -15.31M -17.15M -24.74M -17.78M -14.28M
Issuance of capital stock 21.54M 12.01M 10.60M 0.01M 25.68M
Depreciation 0.00M 0.01M 0.02M 0.03M 0.02M
Other cashflows from investing activities - 0.00M 0.00M 0.00M 0.00M
Dividends paid - 277.12M - - -
Change to account receivables - 0.00M 0.03M -0.03M 0.00M
Other cashflows from financing activities 21.54M 277.12M -0.07M 0.10M -0.08M
Change to netincome - - - 4.73M 4.28M
Capital expenditures 0.00M 0.00M 0.07M 0.06M 0.08M
Change in working capital -0.14M -0.12M 0.70M 1.20M 1.01M
Stock based compensation 0.31M 3.30M 5.41M 4.73M 4.28M
Other non cash items 0.74M 0.77M 0.99M -0.00M -6.28M
Free cash flow -15.31M -17.15M -24.81M -17.84M -14.37M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
GNPX
Genprex Inc		 -0.08
3.73%		 2.06 - - - 1.32 0.18
NVO
Novo Nordisk A/S		 -1.88
4.45%		 40.30 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.17
0.21%		 547.87 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -13.89
1.49%		 916.78 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Genprex Inc

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.

3300 Bee Cave Road, Austin, TX, United States, 78746

877 774 4679

https://www.genprex.com

13

Name Title Year Born
Mr. John Rodney Varner Co-Founder, Chairman, Pres & CEO 1957
Mr. Ryan M. Confer M.S. Chief Financial Officer 1982
Ms. Catherine M. Vaczy Esq. Exec. VP, Gen. Counsel, Corp. Sec. & Chief Strategy Officer 1961
Dr. Hemant Kumar C.P.M., EMBA, Ph.D. Chief Manufacturing & Technology Officer 1963
Ms. Kalyn Dabbs Sr. Mang. of Communications & Marketing NA
Mr. David M. Schloss Sr. VP of HR NA
Mr. Thomas C. Gallagher Esq. Sr. VP of Intellectual Property & Licensing NA
Dr. William E. Gannon Jr. Member of Clinical Advisory Board & VP of Regulatory Affairs NA
Dr. Mark S. Berger M.D. Chief Medical Officer 1955
Mr. Greg Jancarik C.M.A., CPA, M.B.A. Corp. Controller NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

LIF
CAD 21.93
+8.08%
CRON
CAD 5.29
+7.30%
CIA
CAD 2.05
+6.77%
THX
CAD 0.97
+5.43%
OGC
CAD 37.98
+5.38%
GIL
CAD 46.87
-22.45%
IFOS
CAD 1.70
-20.56%
ITH
CAD 1.99
-18.65%
KEEL
CAD 2.41
-17.75%
TNZ
CAD 51.05
-17.39%

Equity Sectors*

  • No sector data available

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…